Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis

Beckwée, David; Leysen, Laurence; Meuwis, Kaipo; Adriaenssens, Nele

doi:10.1007/s00520-017-3613-z

Cited by 101 publications

(80 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, aromatase inhibitors are incorporated as part of the standard adjuvant therapy in predominantly postmenopausal women . Despite the fact that aromatase inhibitors improve disease‐free survival by 10% to 40%, up to 50% of BCS report joint pain as a side effect …”

Section: Discussionmentioning

confidence: 99%

“…62 Despite the fact that aromatase inhibitors improve disease-free survival by 10% to 40%, up to 50% of BCS report joint pain as a side effect. [63][64][65][66][67][68] The underlying mechanism for the pathogenesis of the arthralgia remains a perplexity. A recent study on animals suggests that aromatase inhibitors might selectively target the transient receptor potential ankyrin 1 (TRPA1) channel.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chronic Pain in Breast Cancer Survivors: Nociceptive, Neuropathic, or Central Sensitization Pain?

et al. 2018

Self Cite

View full text Add to dashboard Cite

Introduction The differentiation between acute and chronic pain can be insufficient for appropriate pain management. The aim of this study was to evaluate the prevalence of the predominant pain type (nociceptive, neuropathic, or central sensitization [CS] pain) in breast cancer survivors (BCS) with chronic pain. The secondary aims were to examine (1) differences in health‐related quality of life (HRQoL) between the different pain groups; and (2) the associations between patient‐, disease‐, and treatment‐related factors and the different pain types. Methods To determine the prevalence of the predominant type of pain, a recently proposed classification system was used. BCS were asked to complete the VAS for pain, Douleur Neuropathique 4 Questionnaire, Margolis Pain Diagram, Central Sensitization Inventory, and Short Form 36 (SF‐36). Results Ninety‐one BCS participated, among whom 25.3% presented neuropathic pain, 18.7% nociceptive pain, and 15.4% CS pain. Mixed pain was found in 40.6%. A significant intergroup difference in HRQoL was found for SF‐36 “general health” (P = 0.04). The odds for the presence of CS rather than nociceptive pain are 26 times higher in patients exposed to hormone therapy in comparison to the nonexposed (odds ratio 25.95, 95% confidence interval 1.33 to 504.37, P = 0.03). Conclusion Neuropathic pain is most frequent in BCS. Strong associations were found between CS pain and hormone therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Chronic Pain in Breast Cancer Survivors: Nociceptive, Neuropathic, or Central Sensitization Pain?

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Based on the prior literature on breast cancer treatment, we adjusted for a series of covariates to address potential confounding [5,6]. Covariates included age, year of endocrine therapy initiation, and history of primary tumor resection (lumpectomy or mastectomy), radiation therapy, and chemotherapy (non-taxane based or taxane-based) within a year prior to initiation of endocrine therapy.…”

Section: Covariatesmentioning

confidence: 99%

“…Musculoskeletal problems occur commonly among AI users [3,4], with reported rates ranging widely from 5% to 74% in various studies [5,6]. AI-related musculoskeletal problems such as arthritis and carpal tunnel syndrome may cause substantial pain, impact physical activity and quality of life [5], leading to non-adherence or early discontinuation of AI therapy [7].…”

Section: Introductionmentioning

confidence: 99%

“…AI-related musculoskeletal problems such as arthritis and carpal tunnel syndrome may cause substantial pain, impact physical activity and quality of life [5], leading to non-adherence or early discontinuation of AI therapy [7]. Risk factors of AI-associated musculoskeletal problems are not well established and published results have been inconsistent [6][7][8][9]. For example, one of three cross-sectional studies found that individuals receiving taxane-based chemotherapy were associated with a higher risk (four times higher) of having arthralgia among AI users [8], while two observational studies showed null association [7,9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis

Chien

Yang

Kwoh

et al. 2020

JCM

View full text Add to dashboard Cite

Tamoxifen or aromatase inhibitor (AI) therapy may prevent breast cancer recurrence, however, adverse effects may lead to treatment discontinuation. Evidence regarding the occurrence of AI-associated musculoskeletal problems among Asians is scarce. We identified women with breast cancer-initiating tamoxifen or AIs from the Taiwan National Health Insurance Research Database (2007–2012). Using multivariable cause-specific hazard models, we examined the association between endocrine therapy and the risk of any arthritis and carpal tunnel syndrome, adjusting for age, prior cancer treatment, and other health status factors. Among 32,055 eligible women with breast cancer (mean age = 52.6 ± 11.5 years), 87.4% initiated tamoxifen, 3.9% initiated anastrozole, 8.0% initiated letrozole, and 0.7% initiated exemestane. AI users had a higher 1-year cumulative incidence for any arthritis (13.0% vs. 8.2%, p < 0.0001) and carpal tunnel syndrome (1.4% vs. 0.8%, p = 0.008). Compared to tamoxifen users, AI users had a higher risk of any arthritis [adjusted hazard ratio (aHR) = 1.21, 95%CI = 1.09–1.34] and carpal tunnel syndrome (aHR = 1.68, 95%CI = 1.22–2.32). No significant difference was observed in the risks of any arthritis and carpal tunnel syndrome across different AIs. Taxane use was not associated with any arthritis (aHR = 0.92, 95%CI = 0.81–1.05) or carpal tunnel syndrome (aHR = 0.97, 95%CI = 0.67–1.40) compared to other chemotherapies. Taiwanese women with breast cancer-initiating AIs had an increased risk of arthritis and carpal tunnel syndrome compared to those who initiated tamoxifen.

show abstract

Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer

Roberts

Rickett

Vagenos

et al. 2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis

Abstract: Despite the established benefits of AI, an important portion of the patients experiences AIA. More research is needed to investigate the efficacy of treatments such as exercise therapy for AIA.

Cited by 101 publications

References 56 publications

Chronic Pain in Breast Cancer Survivors: Nociceptive, Neuropathic, or Central Sensitization Pain?

Chronic Pain in Breast Cancer Survivors: Nociceptive, Neuropathic, or Central Sensitization Pain?

Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis

Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer

Contact Info

Product

Resources

About